Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood

Bone Marrow Transplantation

Volumn 40, Issue 4, 2007, Pages 329-333

  Strahm, B ^a   Locatelli, F ^b   Bader, P ^c   Ehlert, K ^d   Kremens, B ^e   Zintl, F ^f   Fuhrer M ^g   Stachel, D ^h   Sykora, K W ⁱ   Sedlacek, P ^j   Baumann, I ^h   Niemeyer, C M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF PAVIA   (Italy)

^c GOETHE UNIVERSITY   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; FOSCARNET; LYMPHOCYTE ANTIBODY; METHOTREXATE; RITUXIMAB; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ARTICLE; CAUSE OF DEATH; CHILD; CHILDHOOD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOPENIA; DONOR; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTION; INFECTIOUS COMPLICATION; MALE; MONOTHERAPY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; REDUCED INTENSITY CONDITIONING; RELAPSE; THROMBOCYTE;

ADOLESCENT; ANEMIA, REFRACTORY; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; PILOT PROJECTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34547637620     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705730     Document Type: Article

References (21)

1. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
2. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program 2004, 118-145.
3. Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997-2003.
4. Locatelli F, Zecca M, Zintl F, Nürnberger W, Ebell W, Niethammer D et al. Busulfan, cyclophosphamide and melphalan as preparative regimen to allogeneic stem cell transplantation in childhood MDS: results of the second interim analysis of the EBMT/EWOG-MDS study. Bone Marrow Transplant 2001; 27 (Suppl 1): S69-S70.
5. Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: The Seattle experience. Bone Marrow Transplant 2004; 33: 805-814.
6. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89 3048-3054.
7. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
8. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
9. Cantu-Rajnoldi A, Fenu S, Kemdrup G, van Wering ER, Niemeyer CM, Baumann I. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS). Ann Hematol 2005; 84: 429-433.
10. Bader P, Niemeyer C, Willasch A, Kreyenberg H, Strahm B, Kremens B et al. Children with myelodysplastic syndrome (MDS) and increasing mixed chimaerism after allogeneic stem cell transplantation have a poor outcome which can be improved by pre-emptive immunotherapy. Br J Haematol 2005; 128: 649-658.
11. Locatelli F, Nollke P, Zecca M, Korthof E, Lanino E, Peters C et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): Results of the EWOG-MDS/EBMT trial. Blood 2005; 105: 410-419.
12. Storb R, Prentice RL, Sullivan KM, Shulman HM, Deeg HJ, Doney KC et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med 1983; 98: 461-466.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
14. Horn B, Baxter-Lowe LA, Englert L, McMillan A. Quinn M, Desantes K et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant 2006; 37: 263-269.
15. Woodard P, Tong X, Richardson S, Srivastava DK, Horwitz EM, Benaim E et al. Etiology and outcome of graft failure in pediatric hematopoietic stem cell transplant recipients. J Pediatr Hematol Oncol 2003; 25: 955-959.
16. Del Toro G, Satwani P, Harrison L, Cheung YK, Brigid BM, George D et al. A pilot study of reduced intensity conditioning and allogeneic stem cell transplantation from unrelated cord blood and matched family donors in children and adolescent recipients. Bone Marrow Transplant 2004; 33: 613-622.
17. Jacobsohn DA, Duerst R, Tse W, Kletzel M. Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156-162.
18. Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005; 35: 345-352.
19. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229-239.
20. Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633-3639.
21. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 1999; 94 2208-2216.